Geron Corporation (0IV3.L)
USD 3.93
(-1.38%)
USD 3.93
(-1.38%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -123.5 Million USD | -192.65% |
| 2022 | -272 Thousand USD | -144.59% |
| 2021 | 610 Thousand USD | 101.22% |
| 2020 | -49.79 Million USD | 1.99% |
| 2019 | -50.81 Million USD | -335.89% |
| 2018 | -11.65 Million USD | -58.13% |
| 2017 | -7.37 Million USD | 13.61% |
| 2016 | -8.53 Million USD | -131.84% |
| 2015 | 26.79 Million USD | 445.86% |
| 2014 | -7.74 Million USD | 1.31% |
| 2013 | -7.85 Million USD | 65.06% |
| 2012 | -22.46 Million USD | -1021.62% |
| 2011 | 2.43 Million USD | -31.57% |
| 2010 | 3.56 Million USD | 106.43% |
| 2009 | 1.72 Million USD | -38.42% |
| 2008 | 2.8 Million USD | -63.22% |
| 2007 | 7.62 Million USD | 132.59% |
| 2006 | 3.27 Million USD | 1030.0% |
| 2005 | 290 Thousand USD | -72.46% |
| 2004 | 1.05 Million USD | -10.31% |
| 2003 | 1.17 Million USD | -5.93% |
| 2002 | 1.24 Million USD | -65.52% |
| 2001 | 3.62 Million USD | -67.86% |
| 2000 | 11.26 Million USD | 23.76% |
| 1999 | 9.1 Million USD | 7.06% |
| 1998 | 8.5 Million USD | -4.49% |
| 1997 | 8.9 Million USD | 36.92% |
| 1996 | 6.5 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 436 Thousand USD | 1403.45% |
| 2024 Q1 | 29 Thousand USD | 113.3% |
| 2023 Q3 | -29.26 Million USD | -11795.12% |
| 2023 Q1 | -230 Thousand USD | -82.54% |
| 2023 Q4 | -218 Thousand USD | 99.26% |
| 2023 Q2 | -246 Thousand USD | -6.96% |
| 2023 FY | -795.99 Thousand USD | -192.65% |
| 2022 FY | -272 Thousand USD | -144.59% |
| 2022 Q1 | -75 Thousand USD | -109.21% |
| 2022 Q2 | -143 Thousand USD | -90.67% |
| 2022 Q3 | -24.3 Million USD | -16897.2% |
| 2022 Q4 | -126 Thousand USD | 99.48% |
| 2021 Q2 | -21.83 Million USD | -4.07% |
| 2021 Q1 | -20.97 Million USD | -42.29% |
| 2021 Q3 | -18.41 Million USD | 15.63% |
| 2021 FY | 610 Thousand USD | 101.22% |
| 2021 Q4 | 814 Thousand USD | 104.42% |
| 2020 Q3 | -13.5 Million USD | -25.02% |
| 2020 Q1 | -6.58 Million USD | 72.53% |
| 2020 FY | -49.79 Million USD | 1.99% |
| 2020 Q2 | -10.8 Million USD | -64.16% |
| 2020 Q4 | -14.74 Million USD | -9.16% |
| 2019 Q3 | -10.97 Million USD | -9.42% |
| 2019 FY | -50.81 Million USD | -335.89% |
| 2019 Q1 | -4.03 Million USD | -9.2% |
| 2019 Q2 | -10.03 Million USD | -148.71% |
| 2019 Q4 | -23.95 Million USD | -118.18% |
| 2018 Q1 | -1.56 Million USD | 11.8% |
| 2018 Q2 | -2.23 Million USD | -42.51% |
| 2018 Q3 | -1.78 Million USD | 20.04% |
| 2018 Q4 | -3.69 Million USD | -106.6% |
| 2018 FY | -11.65 Million USD | -58.13% |
| 2017 FY | -7.37 Million USD | 13.61% |
| 2017 Q1 | -2.04 Million USD | 39.45% |
| 2017 Q3 | -1.88 Million USD | -13.37% |
| 2017 Q2 | -1.66 Million USD | 18.94% |
| 2017 Q4 | -1.77 Million USD | 5.52% |
| 2016 Q3 | 1.53 Million USD | 144.23% |
| 2016 Q1 | -3.22 Million USD | -28.29% |
| 2016 Q4 | -3.38 Million USD | -321.18% |
| 2016 FY | -8.53 Million USD | -131.84% |
| 2016 Q2 | -3.45 Million USD | -7.42% |
| 2015 Q1 | -1.26 Million USD | -6.04% |
| 2015 FY | 26.79 Million USD | 445.86% |
| 2015 Q3 | 32.77 Million USD | 1585.18% |
| 2015 Q2 | -2.2 Million USD | -74.6% |
| 2015 Q4 | -2.51 Million USD | -107.66% |
| 2014 FY | -7.74 Million USD | 1.31% |
| 2014 Q4 | -1.19 Million USD | 62.53% |
| 2014 Q3 | -3.18 Million USD | -65.25% |
| 2014 Q1 | -1.45 Million USD | 29.44% |
| 2014 Q2 | -1.92 Million USD | -32.76% |
| 2013 Q2 | -1.28 Million USD | 36.0% |
| 2013 Q1 | -2 Million USD | 57.73% |
| 2013 FY | -7.85 Million USD | 65.06% |
| 2013 Q4 | -2.05 Million USD | 12.55% |
| 2013 Q3 | -2.35 Million USD | -83.31% |
| 2012 Q2 | 130 Thousand USD | -89.63% |
| 2012 Q3 | 636 Thousand USD | 389.23% |
| 2012 Q4 | -4.73 Million USD | -845.13% |
| 2012 FY | -22.46 Million USD | -1021.62% |
| 2012 Q1 | 1.25 Million USD | 399.6% |
| 2011 Q2 | 462 Thousand USD | -69.3% |
| 2011 FY | 2.43 Million USD | -31.57% |
| 2011 Q4 | 251 Thousand USD | 14.09% |
| 2011 Q1 | 1.5 Million USD | 37.07% |
| 2011 Q3 | 220 Thousand USD | -52.38% |
| 2010 Q1 | 918 Thousand USD | 51.74% |
| 2010 FY | 3.56 Million USD | 106.43% |
| 2010 Q4 | 1.09 Million USD | 108.33% |
| 2010 Q3 | -13.18 Million USD | -1416.88% |
| 2010 Q2 | 1 Million USD | 9.04% |
| 2009 Q4 | 605 Thousand USD | 22.47% |
| 2009 Q2 | 183 Thousand USD | -58.78% |
| 2009 Q1 | 444 Thousand USD | -18.38% |
| 2009 FY | 1.72 Million USD | -38.42% |
| 2009 Q3 | 494 Thousand USD | 169.95% |
| 2008 Q4 | 544 Thousand USD | 48.23% |
| 2008 Q2 | 198 Thousand USD | -88.31% |
| 2008 FY | 2.8 Million USD | -63.22% |
| 2008 Q3 | 367 Thousand USD | 85.35% |
| 2008 Q1 | 1.69 Million USD | -63.86% |
| 2007 Q2 | 889 Thousand USD | -2.95% |
| 2007 Q4 | 4.68 Million USD | 314.78% |
| 2007 FY | 7.62 Million USD | 132.59% |
| 2007 Q1 | 916 Thousand USD | -22.7% |
| 2007 Q3 | 1.13 Million USD | 27.11% |
| 2006 Q4 | 1.18 Million USD | 63.9% |
| 2006 FY | 3.27 Million USD | 1030.0% |
| 2006 Q3 | 723 Thousand USD | -8.02% |
| 2006 Q2 | 786 Thousand USD | 34.82% |
| 2006 Q1 | 583 Thousand USD | 111.4% |
| 2005 Q2 | 4.67 Million USD | 7816.95% |
| 2005 Q4 | -5.11 Million USD | -859.73% |
| 2005 FY | 290 Thousand USD | -72.46% |
| 2005 Q1 | 59 Thousand USD | -82.54% |
| 2005 Q3 | 673 Thousand USD | -85.59% |
| 2004 Q2 | 366 Thousand USD | 47.58% |
| 2004 Q3 | 101 Thousand USD | -72.4% |
| 2004 Q1 | 248 Thousand USD | 60.0% |
| 2004 FY | 1.05 Million USD | -10.31% |
| 2004 Q4 | 338 Thousand USD | 234.65% |
| 2003 Q3 | 472 Thousand USD | 65.61% |
| 2003 Q1 | 36 Thousand USD | -87.71% |
| 2003 Q2 | 285 Thousand USD | 691.67% |
| 2003 Q4 | 155 Thousand USD | -67.16% |
| 2003 FY | 1.17 Million USD | -5.93% |
| 2002 Q2 | 111 Thousand USD | -78.45% |
| 2002 Q3 | 218 Thousand USD | 96.4% |
| 2002 Q4 | 293 Thousand USD | 34.4% |
| 2002 Q1 | 515 Thousand USD | -17.34% |
| 2002 FY | 1.24 Million USD | -65.52% |
| 2001 Q2 | 585 Thousand USD | -67.45% |
| 2001 FY | 3.62 Million USD | -67.86% |
| 2001 Q4 | 623 Thousand USD | 1.3% |
| 2001 Q3 | 615 Thousand USD | 5.13% |
| 2001 Q1 | 1.79 Million USD | -66.25% |
| 2000 Q1 | 1.64 Million USD | -58.83% |
| 2000 Q4 | 5.32 Million USD | 147.79% |
| 2000 Q3 | 2.14 Million USD | 0.37% |
| 2000 FY | 11.26 Million USD | 23.76% |
| 2000 Q2 | 2.14 Million USD | 29.99% |
| 1999 Q3 | 1.7 Million USD | 6.25% |
| 1999 Q2 | 1.6 Million USD | -11.11% |
| 1999 FY | 9.1 Million USD | 7.06% |
| 1999 Q1 | 1.8 Million USD | -25.0% |
| 1999 Q4 | 4 Million USD | 135.29% |
| 1998 Q3 | 1.8 Million USD | 5.88% |
| 1998 Q4 | 2.4 Million USD | 33.33% |
| 1998 Q2 | 1.7 Million USD | -34.62% |
| 1998 Q1 | 2.6 Million USD | -23.53% |
| 1998 FY | 8.5 Million USD | -4.49% |
| 1997 Q1 | 400 Thousand USD | -71.43% |
| 1997 Q4 | 3.4 Million USD | 30.77% |
| 1997 FY | 8.9 Million USD | 36.92% |
| 1997 Q3 | 2.6 Million USD | 4.0% |
| 1997 Q2 | 2.5 Million USD | 525.0% |
| 1996 Q2 | 1.8 Million USD | 20.0% |
| 1996 FY | 6.5 Million USD | 0.0% |
| 1996 Q4 | 1.4 Million USD | -22.22% |
| 1996 Q3 | 1.8 Million USD | 0.0% |
| 1996 Q1 | 1.5 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | -24.089% |
| Dynavax Technologies Corporation | 182.11 Million USD | 167.815% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 123.581% |
| Perrigo Company plc | 1.68 Billion USD | 107.35% |
| Illumina, Inc. | 2.74 Billion USD | 104.501% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.811% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -1191.062% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.466% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 102.357% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 1329.865% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 101.093% |
| Unity Biotechnology, Inc. | -19.69 Million USD | -526.951% |
| Waters Corporation | 1.76 Billion USD | 107.012% |
| Biogen Inc. | 7.3 Billion USD | 101.691% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | -172.483% |
| Evolus, Inc. | 140.52 Million USD | 187.886% |
| Adicet Bio, Inc. | -6.09 Million USD | -1925.303% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 934.818% |
| bluebird bio, Inc. | -4.03 Million USD | -2964.591% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 269.027% |
| FibroGen, Inc. | 128.9 Million USD | 195.81% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 103.564% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | -296.254% |
| Homology Medicines, Inc. | -7.22 Million USD | -1608.438% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 108.137% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 134.114% |
| Myriad Genetics, Inc. | 476.4 Million USD | 125.924% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -42195.548% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 69.031% |
| Zoetis Inc. | 5.83 Billion USD | 102.117% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 40995.033% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 105.694% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 106.485% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 101.435% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -40660.066% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 115.864% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -39357.827% |
| Verastem, Inc. | -62 Thousand USD | -199098.387% |
| Nektar Therapeutics | 53.47 Million USD | 330.942% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 150.505% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | -44.929% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 111.3% |
| OPKO Health, Inc. | 318.12 Million USD | 138.822% |
| Exelixis, Inc. | 1.75 Billion USD | 107.027% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 106.685% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 125.952% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| uniQure N.V. | 2.21 Million USD | 5675.756% |
| Imunon, Inc. | -720 Thousand USD | -17053.075% |
| Blueprint Medicines Corporation | 236.58 Million USD | 152.203% |
| Insmed Incorporated | 239.63 Million USD | 151.538% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 119.392% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 813.107% |
| TG Therapeutics, Inc. | 219.1 Million USD | 156.366% |
| Incyte Corporation | 3.44 Billion USD | 103.59% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 135.912% |